Abstract
In elderly people the respiratory function is affected by anatomical and physiological modifications caused by aging. Elderly COPD patients are characterized by a complexity due to an increasing prevalence of comorbidities related to the age that suggest peculiar care in prescribing the therapy in those patients, also considering other disabilities that are not related with respiratory disorders as physical and mental limitations. Nowadays a therapy that allows modifying the long-term decline in lung function of patients suffering from COPD does not yet exist and, therefore, the treatment of this disease is mainly focused on the administration of bronchodilators and the use of inhaled glucocorticoids. As for younger subjects, also in elderly patients the main classes of bronchodilators used in the treatment of COPD include β2-agonists, anticholinergics and methylxanthines. The inflammatory response suppression represents another mechanistic approach for treating COPD in the elderly, although the use of inhaled corticosteroids is limited to specific indications. Indeed, nowadays there is a strong medical need for novel treatments of COPD in the elderly. These are mainly represented by agents that reduce the spillover of inflammatory mediators from the lung and by compounds that inhibit the chronic systemic inflammatory syndrome. The therapeutic approach of COPD in elderly patients remains a topic of increasing interest, however the development of novel compounds for preventing the COPD progression in the elderly, other than bronchodilators and corticosteroids, remains a challenge.
Keywords: Elderly, aging, COPD, bronchodilator agents, anti-inflammatory agents, combined therapy, adverse effects.
Current Pharmaceutical Design
Title:New Treatments for COPD in the Elderly
Volume: 20 Issue: 38
Author(s): Maria Gabriella Matera, Luigino Calzetta, Paola Rogliani, Alfredo Cesario and Mario Cazzola
Affiliation:
Keywords: Elderly, aging, COPD, bronchodilator agents, anti-inflammatory agents, combined therapy, adverse effects.
Abstract: In elderly people the respiratory function is affected by anatomical and physiological modifications caused by aging. Elderly COPD patients are characterized by a complexity due to an increasing prevalence of comorbidities related to the age that suggest peculiar care in prescribing the therapy in those patients, also considering other disabilities that are not related with respiratory disorders as physical and mental limitations. Nowadays a therapy that allows modifying the long-term decline in lung function of patients suffering from COPD does not yet exist and, therefore, the treatment of this disease is mainly focused on the administration of bronchodilators and the use of inhaled glucocorticoids. As for younger subjects, also in elderly patients the main classes of bronchodilators used in the treatment of COPD include β2-agonists, anticholinergics and methylxanthines. The inflammatory response suppression represents another mechanistic approach for treating COPD in the elderly, although the use of inhaled corticosteroids is limited to specific indications. Indeed, nowadays there is a strong medical need for novel treatments of COPD in the elderly. These are mainly represented by agents that reduce the spillover of inflammatory mediators from the lung and by compounds that inhibit the chronic systemic inflammatory syndrome. The therapeutic approach of COPD in elderly patients remains a topic of increasing interest, however the development of novel compounds for preventing the COPD progression in the elderly, other than bronchodilators and corticosteroids, remains a challenge.
Export Options
About this article
Cite this article as:
Matera Gabriella Maria, Calzetta Luigino, Rogliani Paola, Cesario Alfredo and Cazzola Mario, New Treatments for COPD in the Elderly, Current Pharmaceutical Design 2014; 20 (38) . https://dx.doi.org/10.2174/1381612820666140314154331
DOI https://dx.doi.org/10.2174/1381612820666140314154331 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: Waiting for Action on the Osteoarthritis Front (Guest Editors: Virginia Byers Kraus and Thomas Aigner)]
Current Drug Targets Rheumatoid Arthritis, Immunosenescence and the Hallmarks of Aging
Current Aging Science Bone Marrow Stem Cell Therapy for Myocardial Angiogenesis
Current Vascular Pharmacology Adipose Tissue as a Regulator of Energy Balance
Current Drug Targets Future Therapeutic Strategies in Inflammatory Cardiomyopathy: Insights from the Experimental Autoimmune Myocarditis Model
Cardiovascular & Hematological Disorders-Drug Targets Atherosclerotic Process in Seroreverter Children and Adolescents Exposed to Fetal Antiretroviral Therapy
Current HIV Research The Use of Carvedilol in Pediatric Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Antioxidant Therapy in Diabetic Complications: What is New?
Current Vascular Pharmacology <i>Qiliqiangxin</i> Prescription Promotes Angiogenesis of Hypoxic Primary Rat Cardiac Microvascular Endothelial Cells via Regulating miR-21 Signaling
Current Pharmaceutical Design Estrogen Receptors as Therapeutic Targets in Breast Cancer
Current Topics in Medicinal Chemistry Circulating ACE2 in Cardiovascular and Kidney Diseases
Current Medicinal Chemistry Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics Hypertension, Cognitive Impairment and Dementia: An Epidemiological Perspective
Current Hypertension Reviews Dietary Factors that Affect High Density Lipoprotein Concentrations
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Anti-Atherosclerotic Molecules Targeting Oxidative Stress and Inflammation
Current Pharmaceutical Design Editorial: Time for Earlier and More Intensive Preventive Therapy
Current Vascular Pharmacology The Framingham Brain Donation Program: Neuropathology Along the Cognitive Continuum
Current Alzheimer Research Biomarkers as a Guide of Medical Treatment in Cardiovascular Diseases
Current Medicinal Chemistry Protective Effects of Astragalus Membranaceus and Ligustrazine on Rat Brain Microvascular Endothelial Cell Injury after Oxygen-Glucose Deprivation/ Reoxygenation by Suppressing the PKCδ/MARCKS Pathway
Combinatorial Chemistry & High Throughput Screening Differential Action of Phytochemicals on Platelet Apoptosis: A Biological Overview
Current Medicinal Chemistry